Peer-reviewed publications from the group, newest first. This list covers the last decade of work from Jane Endicott and Martin Noble and their collaborators; preprints are marked. It is generated from ORCID and refreshed periodically.

Hope et al. (2026). FragLite mapping to identify the BRD4 recruitment site of P-TEFb [preprint]. doi: 10.64898/2026.04.09.717428

Rowland et al. (2026). Diversity in CDK structural mechanisms of regulation and drug discovery opportunities. Trends in Biochemical Sciences 51:234-248. doi: 10.1016/j.tibs.2025.12.007

Watt et al. (2025). Different applications and differentiated libraries for crystallographic fragment screening. Current Opinion in Structural Biology 90:102982. doi: 10.1016/j.sbi.2024.102982

Hope et al. (2025). Crystallographic fragment screening of CDK2-cyclin A: FragLites map sites of protein-protein interaction. Structure 33:1971-1983.e3. doi: 10.1016/j.str.2025.07.016

Pastok et al. (2024). Structural requirements for the specific binding of CRABP2 to cyclin D3. Structure 32:2301-2315.e6. doi: 10.1016/j.str.2024.09.020 · PMID: 39419021

Rowland et al. (2024). Cryo-EM structure of the CDK2-cyclin A-CDC25A complex. Nature Communications 15. doi: 10.1038/s41467-024-51135-w

Salvini et al. (2023). Fragment expansion with NUDELs - poised DNA-encoded libraries [preprint]. doi: 10.21203/rs.3.rs-2488317/v1

(2023). Crystallographic fragment screening in academic cancer drug discovery. Methods in Enzymology:211-234. doi: 10.1016/bs.mie.2023.06.021 · PMID: 37858530

Rowland et al. (2023). Cryo-EM structure of SKP1-SKP2-CKS1 in complex with CDK2-cyclin A-p27KIP1. Scientific Reports 13. doi: 10.1038/s41598-023-37609-9 · PMID: 37400515

Miller et al. (2022). Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. Journal of Medicinal Chemistry 65:6513-6540. doi: 10.1021/acs.jmedchem.1c01756 · PMID: 35468293

Davison et al. (2022). Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites─Halogenated Probes of Druglike and Peptide-like Molecular Interactions. Journal of Medicinal Chemistry 65:15416-15432. doi: 10.1021/acs.jmedchem.2c01357 · PMID: 36367089

Martin & Noble (2022). Exiting the tunnel of uncertainty: crystal soak to validated hit. Acta Crystallographica Section D Structural Biology 78:1294-1302. doi: 10.1107/S2059798322009986

Chessari et al. (2021). Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction. Journal of Medicinal Chemistry 64:4071-4088. doi: 10.1021/acs.jmedchem.0c02188 · PMID: 33761253

Salamina et al. (2021). Discriminative SKP2 Interactions with CDK-Cyclin Complexes Support a Cyclin A-Specific Role in p27KIP1 Degradation. Journal of Molecular Biology 433:166795. doi: 10.1016/j.jmb.2020.166795 · PMID: 33422522

Al-Khawaldeh et al. (2021). An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase. Journal of Medicinal Chemistry 64:10001-10018. doi: 10.1021/acs.jmedchem.0c01249 · PMID: 34212719

Lochhead et al. (2020). Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nature Communications 11. doi: 10.1038/s41467-020-15031-3

Douangamath et al. (2020). Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nature Communications 11. doi: 10.1038/s41467-020-18709-w · PMID: 33028810

Verhoork et al. (2019). Tuning the Binding Affinity and Selectivity of Perfluoroaryl‐Stapled Peptides by Cysteine‐Editing. Chemistry – A European Journal 25:177-182. doi: 10.1002/chem.201804163

Myers et al. (2019). Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4. European Journal of Medicinal Chemistry 178:530-543. doi: 10.1016/j.ejmech.2019.05.057

Wood et al. (2019). FragLites—Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation. Journal of Medicinal Chemistry 62:3741-3752. doi: 10.1021/acs.jmedchem.9b00304

Wood et al. (2019). Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell Chemical Biology 26:121-130.e5. doi: 10.1016/j.chembiol.2018.10.015

Adams et al. (2019). Announcing mandatory submission of PDBx/mmCIF format files for crystallographic depositions to the Protein Data Bank (PDB). Acta Crystallographica Section D Structural Biology 75:451-454. doi: 10.1107/S2059798319004522

Unterlass et al. (2018). Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. Oncotarget 9:13139-13153. doi: 10.18632/oncotarget.11487

Wood & Endicott (2018). Structural insights into the functional diversity of the CDK–cyclin family. Open Biology 8. doi: 10.1098/rsob.180112

Whittaker et al. (2018). Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor. Molecular Oncology 12:287-304. doi: 10.1002/1878-0261.12148 · PMID: 29063678

Miller et al. (2018). Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach. Organic & Biomolecular Chemistry 16:1843-1850. doi: 10.1039/c8ob00099a · PMID: 29469144

Potterton et al. (2018). CCP4i2: the new graphical user interface to theCCP4 program suite. Acta Crystallographica Section D Structural Biology 74:68-84. doi: 10.1107/s2059798317016035 · PMID: 29533233

Martin et al. (2017). Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays in Biochemistry 61:439-452. doi: 10.1042/ebc20170040 · PMID: 29118092

Unterlass et al. (2017). Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH). Oncotarget 8:104478-104491. doi: 10.18632/oncotarget.22327 · PMID: 29262655

Hallett et al. (2017). Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System. Cell Reports 21:1386-1398. doi: 10.1016/j.celrep.2017.10.042 · PMID: 29091774

Coxon et al. (2017). Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry 60:1746-1767. doi: 10.1021/acs.jmedchem.6b01254 · PMID: 28005359

Vilar-González et al. (2017). Could Omega 3 Supplements Play a Role in the Prevention of Neurocognitive Impairment in Cancer Patients?. Clinical Oncology 29:e48. doi: 10.1016/j.clon.2016.09.013

Jones et al. (2017). Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer. Scientific Reports 7. doi: 10.1038/srep40957 · PMID: 28205582

Tan et al. (2016). Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design. The Journal of Physical Chemistry Letters 7:3452-3457. doi: 10.1021/acs.jpclett.6b01525